Panagora Asset Management’s Neuropace NPCE Stock Holding History

Panagora Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$825K	Sell	59,974 -54,085	-47%	-$802K	﹤0.01%	834
2026 Q2	$1.81M	Sell	114,059 -216	-0.2%	-$3.48K	0.01%	656
2026 Q1	$1.5M	Buy	114,275 +56,267	+97%	+$844K	0.01%	635
2025 Q4	$896K	Sell	58,008 -1,687	-3%	-$22.6K	﹤0.01%	749
2025 Q3	$615K	Sell	59,695 -40,094	-40%	-$378K	﹤0.01%	758
2025 Q2	$1.11M	Buy	+99,789	New	+$1.25M	0.01%	605

Other funds holding NPCE

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

Legato Capital Management San Francisco, California $1.11B AUM 60.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Panagora Asset Management's NPCE Position: Q3 2026 in Review

Panagora Asset Management reduced its Neuropace (NPCE) stake by 47% in Q3 2026, selling an estimated $802K and leaving 59,974 shares worth $825K. The position accounts for ﹤0.01% of the portfolio, ranked #834.

Panagora Asset Management first reported a position in NPCE in Q2 2025 and has held it in 6 quarters since. The position peaked at $1.81M in Q2 2026. 47 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

Panagora Asset Management held 59,974 shares of Neuropace worth $825K as of Q3 2026.
Panagora Asset Management sold 54,085 Neuropace shares in Q3 2026, an estimated $802K.
Neuropace made up ﹤0.01% of Panagora Asset Management's portfolio in Q3 2026, its #834 holding.
Panagora Asset Management first reported a position in Neuropace in Q2 2025 and has held it in 6 quarters since.
Panagora Asset Management's Neuropace position peaked at $1.81M in Q2 2026.
47 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Panagora Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.